Peptide-based immunotherapeutics for synucleinopathies

Project Details


Dieses Projekt steht im Zusammenhang mit einem FFG-Kleinprojekt, dass Tridem eingereicht hat. Wir schließen einen Kooperationsvertrag mit Tridem ab.

Tridem Bioscience GmbH & Co KG is developing peptide-based immunotherapeutics for the treatment of chronic human conditions, especially synucleinopathies. Assoc.Prof. Richard Weiss has a long standing experience in the specific immunotherapy viathe skin and formulations for topical targeted delivery with the goal of immunization.
By combining the two areas of expertise in this project, we will develop novel peptide based vaccines targeting immune cells in the skin. The potential of the new vaccine formulations to induce therapeutic antibodies will be tested in mouse models of skin vaccination.
AcronymCooperation TRIDEM
Effective start/end date1/10/2030/09/21